Table 2 |
|||
|
Summary of adverse events recorded during the study |
|||
| Adverse event |
DHA-PQP |
ALN |
P-value |
|
|
|||
| Headache |
43 (58.9%) |
37 (50.7%) |
0.318 |
| Abdominal pain |
25 (32.4%) |
26 (35.6%) |
0.862 |
| Weakness |
19 (26.0%) |
30 (41.1%) |
0.035 |
| Anorexia |
8 (10.9%) |
10 (13.7%) |
0.439 |
| Diarrhea |
9 (12.3%) |
7 (9.6%) |
0.785 |
| Cough |
16 (21.9%) |
17 (23.3%) |
0.843 |
| Vomiting |
11 (15.1%) |
9 (12.3%) |
0.806 |
| Pruritis |
4 (5.5%) |
3 (4.1%) |
0.698 |
|
|
|||
|
Mens et al. Malaria Journal 2008 7:237 doi:10.1186/1475-2875-7-237 |
|||
